Geron Corp Stock Price, News & Analysis

Geron Corporation (GERN) has granted equity awards totaling 411,000 shares to six new employees as employment inducement. The awards, granted on May 16, 2025, consist of:

- Stock options to purchase 274,000 shares at $1.27 per share (closing price on grant date), with a 10-year term and 4-year vesting schedule

- Restricted Stock Units (RSUs) representing 137,000 shares, vesting 25% annually over 4 years

The grants were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan terms.

Geron (Nasdaq: GERN) has granted equity awards totaling 1,551,000 shares to twelve new employees as employment inducement. The grants, issued on April 17, 2025, include:

• 1,034,000 shares as stock options with $1.27 per share exercise price
• 517,000 shares as restricted stock units (RSUs)

The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining over 42 months. RSUs vest 25% annually over four years. These awards were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan.

Geron (GERN) has scheduled the release of its first quarter 2025 financial results before market opening on Wednesday, May 7, 2025. The company will distribute the results via press release, which will be accessible on their investor relations website.

Following the release, Geron will host a conference call at 8:00 a.m. Eastern Time to discuss financial performance and business highlights. Investors can access a live webcast of the conference call and accompanying presentation through the company's website, with the recording remaining available for 30 days afterward.

Geron (Nasdaq: GERN) has announced the granting of equity awards to three newly hired employees as inducement for their employment. The awards, granted on March 17, 2025, consist of:

• 150,000 shares in stock options with an exercise price of $1.74 per share
• 75,000 shares in restricted stock units (RSUs)

The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining shares vesting over 42 months. RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Geron (GERN) has received European Commission (EC) approval for RYTELO® (imetelstat), the first-in-class telomerase inhibitor for treating adults with transfusion-dependent anemia due to lower-risk MDS (LR-MDS). The approval applies to patients without del-5q abnormality who are either ineligible for or had unsatisfactory response to erythropoietin-based therapy.

The approval is based on the IMerge Phase 3 clinical trial results, which showed significant reduction in red blood cell transfusion dependency during the first 24 weeks compared to placebo. The most common adverse reactions included neutropenia (69%) and thrombocytopenia (63%), typically resolving within four weeks.

RYTELO's marketing authorization covers all 27 EU member states, Iceland, Norway, and Liechtenstein. Geron plans to commercialize RYTELO in select EU countries starting in 2026, pending reimbursement approvals. The drug maintains orphan drug designation, providing 10-year market exclusivity, with patent exclusivity anticipated until 2038.

Geron (Nasdaq: GERN) announced significant leadership changes, with CEO John 'Chip' A. Scarlett set to depart on March 31, 2025. Board member Dawn Carter Bir has been appointed as Interim President and CEO, effective immediately, while Elizabeth G. O'Farrell becomes Chair of the Board.

The company, which recently achieved FDA approval for its first commercial product RYTELO® (imetelstat) for treating certain patients with lower-risk MDS, is now searching for a new CEO with substantial commercial experience. Under Scarlett's 14-year leadership, Geron also advanced a potential second indication for treating JAK inhibitor relapsed/refractory myelofibrosis into a Phase 3 registrational trial.

Geron (GERN) reported strong Q4 2024 financial results, achieving $47.5 million in RYTELO™ net product revenue in Q4 and $76.5 million since its June 2024 launch. The company ended 2024 with $502.9 million in cash and equivalents.

Key financial metrics include a Q4 net loss of $25.4 million ($0.04 per share) and full-year net loss of $174.6 million ($0.27 per share). Operating expenses totaled $67.6 million for Q4 and $250.7 million for 2024.

Notable developments include receiving positive CHMP opinion for RYTELO in Europe, with expected approval in H1 2025 and commercialization in select EU countries in 2026. The Phase 3 IMpactMF trial reached 80% enrollment, with interim analysis expected in H2 2026.

Geron (Nasdaq: GERN), a commercial-stage biopharmaceutical company, has announced its management team's upcoming participation in three major healthcare investor conferences in March 2025:

• TD Cowen 45th Annual Health Care Conference - March 3rd at 3:10pm ET in Boston, MA
• Leerink Global Healthcare Conference - March 10th at 3:00pm ET in Miami, FL
• Barclays 27th Annual Global Healthcare Conference - March 11th at 10:30am ET in Miami, FL

The company will participate in fireside chats at each event. Live webcasts will be accessible through the Investors & Media section of Geron's website under Events, with replays available for 30 days after each presentation.